Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18386011 | 0.82 | HDAC4 (0.50) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL106257 | 0.82 | HDAC4 (0.57) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| Bromomethane SCHEMBL4427405 | 0.78 | HDAC4 (0.53) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL28763580 | 0.78 | GAA (0.45) | LMNACA1CA2GAACA12 | |
| SCHEMBL1981762 | 0.78 | HDAC3 (0.44) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL9673769 | 0.78 | HDAC3 (0.44) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL3331522 | 0.77 | MAPT (0.46) | ALDH1A1LMNAPOLBGAAMAPT | |
| SCHEMBL16253852 | 0.72 | KMT2A (0.48) | CA1CA2KMT2A | |
| Water SCHEMBL18063169 | 0.71 | HDAC4 (0.49) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL1934604 | 0.69 | CA1 (0.43) | CA1CA2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027073-A1 | Long-acting derivatives of pyy agonists | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2007-02-01 | — | — | US | claimed |
| WO-2004089279-A2 | LONG-ACTING DERIVATIVES OF PYY AGONISTS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-10-21 | — | — | WO | claimed |
| US-20240209055-A1 | PROTEIN TYROSINE-TYROSINE ANALOGS AND METHODS OF USING THE SAME | ELI LILLY AND COMPANY | 2024-06-27 | — | — | US | disclosed |
| US-11820803-B2 | Protein tyrosine-tyrosine analogs and methods of using the same | ELI LILLY AND COMPANY (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220025009-A1 | PROTEIN TYROSINE-TYROSINE ANALOGS AND METHODS OF USING THE SAME | ELI LILLY AND COMPANY | 2022-01-27 | — | — | US | disclosed |
| US-11155592-B2 | Protein tyrosine-tyrosine analogs and methods of using the same | ELI LILLY AND COMPANY (US) | 2021-10-26 | — | — | US | disclosed |
| EP-3873924-A1 | PROTEIN TYROSINE-TYROSINE ANALOGS AND METHODS OF USING THE SAME | Eli Lilly and Company (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-112888705-A | Protein tyrosine-tyrosine analogs and methods of use thereof | 伊莱利利公司 | 2021-06-01 | — | — | CN | disclosed |
| US-20200140514-A1 | PROTEIN TYROSINE-TYROSINE ANALOGS AND METHODS OF USING THE SAME | LILLY CO ELI (US) | 2020-05-07 | — | — | US | disclosed |
| US-9956295-B2 | Reversible pegylated drugs | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-05-01 | — | — | US | disclosed |
| US-20160324975-A1 | REVERSIBLE PEGYLATED DRUGS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-11-10 | — | — | US | disclosed |
| US-20070027073-A1 | Long-acting derivatives of pyy agonists | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2007-02-01 | — | — | US | disclosed |
| US-20070027073-A1 | Long-acting derivatives of pyy agonists | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2007-02-01 | — | — | US | disclosed |
| US-20060171920-A1 | derivatization of the drug with 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) removable under mild basic conditions by attaching a protein or polymer carrier to derivatized drug molecule,such carrier serving for delivery of the drug | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2006-08-03 | — | — | US | disclosed |
| EP-1620118-A2 | REVERSIBLE PEGYLATED DRUGS | YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004089279-A3 | LONG-ACTING DERIVATIVES OF PYY AGONISTS | YEDA RES & DEV (IL) | 2005-04-28 | — | — | WO | disclosed |
| WO-2004089280-A2 | REVERSIBLE PEGYLATED DRUGS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089279-A2 | LONG-ACTING DERIVATIVES OF PYY AGONISTS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089279-A2 | LONG-ACTING DERIVATIVES OF PYY AGONISTS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-10-21 | — | — | WO | disclosed |
| US-20040092443-A1 | Hyperglycemic agents; antidiabetic agents | YEDA RESEARCH AND DEVELOPMENT CO., LTD (IL) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060171920-A1 | derivatization of the drug with 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) removable under mild basic conditions by attaching a protein or polymer carrier to derivatized drug molecule,such carrier serving for delivery of the drug | PTMS, FIBP, FLT3 | HDAC3 449/4885HDAC4 1888/4885HDAC7 1395/4885 |
| US-11820803-B2 | Protein tyrosine-tyrosine analogs and methods of using the same | NPY2R, NPY1R, NPY5R | HDAC3 4370/4885HDAC4 4528/4885HDAC7 4277/4885 |
| US-20240209055-A1 | PROTEIN TYROSINE-TYROSINE ANALOGS AND METHODS OF USING THE SAME | NPY2R, NPY1R, NPY5R | HDAC3 4370/4885HDAC4 4528/4885HDAC7 4277/4885 |
| US-11155592-B2 | Protein tyrosine-tyrosine analogs and methods of using the same | NPY2R, NPY1R, NPY5R | HDAC3 4370/4885HDAC4 4528/4885HDAC7 4277/4885 |
| US-20160324975-A1 | REVERSIBLE PEGYLATED DRUGS | PTMS, FIBP, FLT3 | HDAC3 632/4885HDAC4 2351/4885HDAC7 2012/4885 |
| US-20220025009-A1 | PROTEIN TYROSINE-TYROSINE ANALOGS AND METHODS OF USING THE SAME | NPY2R, NPY1R, NPY5R | HDAC3 4370/4885HDAC4 4528/4885HDAC7 4277/4885 |
| US-20200140514-A1 | PROTEIN TYROSINE-TYROSINE ANALOGS AND METHODS OF USING THE SAME | NPY2R, NPY1R, NPY5R | HDAC3 4370/4885HDAC4 4528/4885HDAC7 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.